Xiaoyang Luo1, Wanxia He1, Xiangyou Hu1, Riqiang Yan2. 1. Department of Neurosciences, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio. 2. Department of Neurosciences, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio. Electronic address: yanr@ccf.org.
Abstract
BACKGROUND: Neuregulin-1 (Nrg1) is a pleiotropic signaling molecule that regulates neural development, and mutation of Nrg1 is a risk factor for schizophrenia. Cleavage of type I β1 Nrg1 isoform by Bace1 releases a secreted N-terminal fragment (Nrg1-ntfβ), which can bind to a cognate ErbB receptor to activate the specific signaling cascade. This study aimed to determine whether increased expression of Nrg1 is beneficial for brain development and functions. METHODS: We generated transgenic mice overexpressing this fragment under the control of a tetracycline-inducible promoter and examined functional and behavioral changes in mice upon reversible expression of the transgene. RESULTS: Increased expression of full-length Nrg1 in mouse neurons has been previously shown to enhance myelination in the central nervous system. Overexpressing Nrg1-ntfβ enhanced the expression of myelin proteins, consistent with the expected activation of the Nrg1 signaling pathway by Nrg1-ntfβ. Contrary to expectations, overexpressing Nrg1-ntfβ transgene caused schizophrenia-like behaviors in transgenic mice, and these abnormal behaviors were reversible if the expression of the Nrg1-ntfβ transgene was turned off. Our molecular assay suggests that protein levels of N-methyl-D-aspartate receptors are reduced in this transgenic mouse model, which might underlie the observed social and cognitive behavioral impairments. CONCLUSIONS: Our results indicate that overexpressing the secreted form of Nrg1 is sufficient to cause schizophrenia-like behaviors in a mouse model, meaning the effect is independent of the transmembrane and C-terminal domains of Nrg1. Hence, genetic gain-of-function mutations of Nrg1 are also risk factors for schizophrenia.
BACKGROUND:Neuregulin-1 (Nrg1) is a pleiotropic signaling molecule that regulates neural development, and mutation of Nrg1 is a risk factor for schizophrenia. Cleavage of type I β1 Nrg1 isoform by Bace1 releases a secreted N-terminal fragment (Nrg1-ntfβ), which can bind to a cognate ErbB receptor to activate the specific signaling cascade. This study aimed to determine whether increased expression of Nrg1 is beneficial for brain development and functions. METHODS: We generated transgenic mice overexpressing this fragment under the control of a tetracycline-inducible promoter and examined functional and behavioral changes in mice upon reversible expression of the transgene. RESULTS: Increased expression of full-length Nrg1 in mouse neurons has been previously shown to enhance myelination in the central nervous system. Overexpressing Nrg1-ntfβ enhanced the expression of myelin proteins, consistent with the expected activation of the Nrg1 signaling pathway by Nrg1-ntfβ. Contrary to expectations, overexpressing Nrg1-ntfβ transgene caused schizophrenia-like behaviors in transgenic mice, and these abnormal behaviors were reversible if the expression of the Nrg1-ntfβ transgene was turned off. Our molecular assay suggests that protein levels of N-methyl-D-aspartate receptors are reduced in this transgenicmouse model, which might underlie the observed social and cognitive behavioral impairments. CONCLUSIONS: Our results indicate that overexpressing the secreted form of Nrg1 is sufficient to cause schizophrenia-like behaviors in a mouse model, meaning the effect is independent of the transmembrane and C-terminal domains of Nrg1. Hence, genetic gain-of-function mutations of Nrg1 are also risk factors for schizophrenia.
Authors: Xiangyou Hu; Caitlin W Hicks; Wanxia He; Philip Wong; Wendy B Macklin; Bruce D Trapp; Riqiang Yan Journal: Nat Neurosci Date: 2006-11-12 Impact factor: 24.884
Authors: Jeremy Hall; Heather C Whalley; Dominic E Job; Ben J Baig; Andrew M McIntosh; Kathryn L Evans; Pippa A Thomson; David J Porteous; David G Cunningham-Owens; Eve C Johnstone; Stephen M Lawrie Journal: Nat Neurosci Date: 2006-10-29 Impact factor: 24.884
Authors: Sophie Belin; Francesca Ornaghi; Ghjuvan'Ghjacumu Shackleford; Jie Wang; Cristina Scapin; Camila Lopez-Anido; Nicholas Silvestri; Neil Robertson; Courtney Williamson; Akihiro Ishii; Carla Taveggia; John Svaren; Rashmi Bansal; Markus H Schwab; Klaus Nave; Pietro Fratta; Maurizio D'Antonio; Yannick Poitelon; M Laura Feltri; Lawrence Wrabetz Journal: Hum Mol Genet Date: 2019-04-15 Impact factor: 6.150
Authors: D-M Yin; Y-J Chen; S Liu; H Jiao; C Shen; A Sathyamurthy; T W Lin; W-C Xiong; B-M Li; L Mei; C Bergson Journal: Mol Psychiatry Date: 2014-10-28 Impact factor: 15.992
Authors: R Madelaine Paredes; E Piccart; E Navaira; D Cruz; M A Javors; W Koek; M J Beckstead; C Walss-Bass Journal: Genes Brain Behav Date: 2015-05-21 Impact factor: 3.449
Authors: Sarah L Ferri; Ashley A Pallathra; Hyong Kim; Holly C Dow; Praachi Raje; Mary McMullen; Warren B Bilker; Steven J Siegel; Ted Abel; Edward S Brodkin Journal: Genes Brain Behav Date: 2019-12-12 Impact factor: 3.449